Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib with pembrolizumab/carboplatin/pemetrexed in untreated advanced non-squamous NSCLC
NCT05469178Phase 2Terminated
- Sponsor
- BerGenBio ASA
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of bemcentinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by BerGenBio ASA. Primary endpoints: Dose Limiting Toxicity at 21 days and Objective Response Rate at 12 months. Started Mar 2023; status: terminated.
02
Drugs
bemcentinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05469178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469178.